Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Solaris Energy Infrastructure, Actinium Pharmaceuticals, Bakkt Holdings, and Cerevel Therapeutics, with specific allegations of misleading statements and omissions of material facts regarding their business operations and prospects [1]. Solaris Energy Infrastructure, Inc. (NYSE: SEI) - Class period is from July 9, 2024, to March 17, 2025, with a lead plaintiff deadline of May 27, 2025 [2]. - Allegations include failure to disclose that Mobile Energy Rentals LLC had minimal corporate history, lacked a diversified earnings stream, and was co-owned by a convicted felon associated with turbine-related fraud [2]. - Claims that Solaris overstated commercial prospects from an acquisition and inflated profitability metrics by not properly depreciating turbines, leading to materially misleading statements [2]. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) - Class period is from October 31, 2022, to August 2, 2024, with a lead plaintiff deadline of May 26, 2025 [3]. - The complaint alleges that Actinium made false claims regarding the strength of data submitted to the FDA for its Biologics License Application for Iomab-B, later admitting the need for additional clinical trials [3]. - Public statements were deemed materially misleading, resulting in investor damages when the truth was revealed [3]. Bakkt Holdings, Inc. (NYSE: BKKT) - Class period is from March 25, 2024, to March 17, 2025, with a lead plaintiff deadline of June 2, 2025 [4]. - Allegations include misrepresentation of the stability and diversity of crypto services revenue, which was heavily reliant on a single contract with Webull [4]. - Positive statements about the company's business were claimed to be materially misleading due to undisclosed dependencies [4]. Cerevel Therapeutics Holdings, Inc. (CERE) - Class period is from October 11, 2023, to August 1, 2024, with a lead plaintiff deadline of June 3, 2025 [6]. - The complaint alleges that Cerevel's offering documents omitted material facts about AbbVie's interest in acquiring the company at a significantly higher price than the offering price of $22.81 per share [6]. - Claims that Cerevel's controlling shareholder acquired shares at an artificially depressed price while possessing nonpublic information, leading to a substantial windfall when AbbVie announced the acquisition at$45 per share [6][7].